Bologna, Italy – A new multi-center investigation has uncovered significant differences in the gut microbiome of children newly diagnosed with acute lymphoblastic leukemia (ALL), the most common childhood cancer. Using high-resolution shotgun metagenomic sequencing, researchers analyzed stool samples from 30 pediatric ALL patients across Italy and compared them with 176...
treatment News
Portland, OR – New research from Oregon Health & Science University suggests that people with multiple sclerosis, or MS, could benefit from a low-fat diet to improve the fatigue that’s a debilitating, and often-underappreciated, symptom of the condition. The study, published online Wednesday in the Multiple Sclerosis Journal, is the latest in...
Barcelona, Spain – Pau Gorostiza, an ICREA research professor and principal investigator of the Nanoprobes and Nanoswitches group at the Institute for Bioengineering of Catalonia (IBEC) and CIBER-BBN, is set to coordinate the PHOTOTHERAPORT project, which is funded by the prestigious Pathfinder Open programme of the European Innovation Council (EIC)....
AUSTIN, Texas — Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has launched two new cystic fibrosis (CF) tests in Europe, the xTAG® Cystic Fibrosis 39 Kit v2 and xTAG® Cystic Fibrosis 71 Kit v2, as CE IVD Marked products under the European Directive...
SEATTLE, WA — LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the initiation of the largest PBM trial ever conducted in patients with dry age-related macular degeneration (AMD). A global registry data collection from patients treated with PBM using the Valeda®...
SEATTLE, WA — LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced an update on the regulatory status of the Valeda® Light Delivery System. Following feedback from the FDA, a De Novo request to reclassify the Valeda Light Delivery System as a...
AUSTIN, Texas – Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that the OraGrowtH212 Trial, a Phase 2 PK/PD study of the company’s lead asset LUM-201 for the treatment of patients with pediatric growth hormone deficiency (PGHD), is open for enrollment. Lumos...
Webinar to be Held December 6, 2023 at 1:30pm EST AUSTIN, Texas — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD), announced today that the Company will host a key opinion leader (KOL) webinar to discuss topline results...
Austin, Texas — Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in Oppenheimer’s 33rd Annual Healthcare Conference held virtually March 13-15, 2023. Lumos Pharma will present and host virtual one-on-one...
SEOUL, South Korea — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study featuring Lunit SCOPE IO, Lunit’s AI-powered analyzer for quantitative immune phenotyping from H&E. The study was recently published in Clinical Cancer Research (CCR), an international...